Positive News SentimentPositive NewsNASDAQ:NAUT Nautilus Biotechnology (NAUT) Stock Price, News & Analysis $2.32 -0.06 (-2.52%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$2.27 -0.05 (-2.33%) As of 11/13/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nautilus Biotechnology Stock (NASDAQ:NAUT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nautilus Biotechnology alerts:Sign Up Key Stats Today's Range$2.21▼$2.4050-Day Range$0.89▼$3.2452-Week Range$0.84▼$4.31Volume1.88 million shsAverage Volume8.70 million shsMarket Capitalization$295.50 millionP/E RatioN/ADividend YieldN/APrice Target$3.83Consensus RatingModerate Buy Company Overview Nautilus Biotechnology develops a platform designed to measure and analyze proteins at scale. Its approach combines technologies such as protein engineering, nanotechnology and computational analysis to help researchers study the proteome—the full set of proteins produced by a cell, tissue or organism. The company’s platform is intended for applications in biological research and drug development, including investigating how proteins relate to health and disease. Nautilus has described its technology as aiming to provide broad, detailed protein measurements that can support research across a range of biological samples. Founded in 2016 by Sujal Patel and Parag Mallick, Nautilus is led by Patel, who serves as chief executive officer. The company is based in Seattle, Washington, and focuses on developing its protein-analysis technology for the life sciences research community.AI Generated. May Contain Errors. Read More Nautilus Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreNAUT MarketRank™: 2.950163934425 of 5 starsNautilus Biotechnology scored higher than 59% of companies evaluated by MarketBeat, and ranked 400th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingNautilus Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialNautilus Biotechnology has a consensus price target of $3.83, representing about 65.2% upside from its current price of $2.32.Amount of Analyst CoverageNautilus Biotechnology has only been the subject of 4 research reports in the past 90 days.Read more about Nautilus Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nautilus Biotechnology are expected to decrease in the coming year, from ($0.50) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nautilus Biotechnology is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nautilus Biotechnology is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNautilus Biotechnology has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.78% of the float of Nautilus Biotechnology has been sold short.Short Interest Ratio / Days to CoverNautilus Biotechnology has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nautilus Biotechnology has recently increased by 3.91%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNautilus Biotechnology does not currently pay a dividend.Dividend GrowthNautilus Biotechnology does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentNautilus Biotechnology has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nautilus Biotechnology this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for NAUT on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows5 people have added Nautilus Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nautilus Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders41.10% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nautilus Biotechnology's insider trading history. Receive NAUT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAUT Stock News HeadlinesNautilus: 3 key takeaways for long-term investorsNovember 5, 2026 | msn.comNautilus Biotechnology: Bullish On Voyager's Upcoming LaunchOctober 29, 2026 | seekingalpha.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 14 at 1:00 AM | Behind the Markets (Ad)Nautilus Biotechnology Reports Q3 Results; Expects Up To $6M From ARPA-H-Funded ConsortiumOctober 28, 2026 | rttnews.comNautilus outlines 20 proteoform assays by mid-2028 while exploring funding by mid-2027October 27, 2026 | seekingalpha.comNautilus Biotechnology, Inc. Q3 2026 Earnings Call SummaryOctober 27, 2026 | finance.yahoo.comNautilus (NAUT) Q3 2026 Earnings Call TranscriptOctober 27, 2026 | finance.yahoo.comNautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 27, 2026 | marketscreener.comMSee More Headlines NAUT Stock Analysis - Frequently Asked Questions How have NAUT shares performed this year? Nautilus Biotechnology's stock was trading at $1.95 at the start of the year. Since then, NAUT shares have increased by 19.0% and is now trading at $2.32. How were Nautilus Biotechnology's earnings last quarter? Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its earnings results on Tuesday, October, 27th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The company had revenue of $234 thousand for the quarter, compared to analysts' expectations of $206 thousand. Read the conference call transcript. Who are Nautilus Biotechnology's major shareholders? Nautilus Biotechnology's top institutional shareholders include State Street Corp (0.45%), Russell Investments Group Ltd. (0.22%), Empowered Funds LLC (0.06%) and TD Waterhouse Canada Inc. (0.02%). Insiders that own company stock include Parag Mallick, Sujal M Patel, Ah Equity Partners Bio Ii, LL, Anna Mowry, Matthew B Murphy, Kentaro Suzuki and Mary E Godwin. View institutional ownership trends. How do I buy shares of Nautilus Biotechnology? Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nautilus Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include Illumina (ILMN), NVIDIA (NVDA), Roku (ROKU), JPMorgan Chase & Co. (JPM), Teladoc Health (TDOC), Uber Technologies (UBER) and Amgen (AMGN). Company Calendar Last Earnings10/27/2026Today11/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NAUT's financial health is in the Green zone, according to TradeSmith. NAUT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:NAUT CIK1808805 Webwww.nautilus.bio Phone206-333-2001FaxN/AEmployees130Year Founded2016Price Target and Rating Average Price Target for Nautilus Biotechnology$3.83 High Price Target$4.00 Low Price Target$3.50 Potential Upside/Downside+65.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59 million Net MarginsN/A Pretax Margin-13,816.75% Return on Equity-42.68% Return on Assets-34.39% Debt Debt-to-Equity RatioN/A Current Ratio9.25 Quick Ratio9.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book2.52Miscellaneous Outstanding Shares127,370,000Free Float75,022,000Market Cap$295.50 million OptionableOptionable Beta0.66 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:NAUT) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredLog into Keith’s $5,000 AI Signals Trading system todayA new AI system from the TradeSmith Daily team shows trades taking shape 90 minutes before they occur, with 93...TradeSmith | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nautilus Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nautilus Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
